mexiletine and Myotonia

mexiletine has been researched along with Myotonia in 28 studies

Mexiletine: Antiarrhythmic agent pharmacologically similar to LIDOCAINE. It may have some anticonvulsant properties.
mexiletine : An aromatic ether which is 2,6-dimethylphenyl ether of 2-aminopropan-1-ol.

Myotonia: Prolonged failure of muscle relaxation after contraction. This may occur after voluntary contractions, muscle percussion, or electrical stimulation of the muscle. Myotonia is a characteristic feature of MYOTONIC DISORDERS.

Research

Studies (28)

Authors

Clinical Trials (3)

Trial Overview

Trial Outcomes

Mean Change From Baseline in Ambulation Using the 6 Minute Walk Distance

During this assessment, participants were asked to walk as far as they could back and forth on a fixed 20 meter route for 6 minutes. The total distance walked during the 6 minutes was recorded in meters. Change from baseline was defined as the difference between the average 6 minute walk distance at baseline and the average 6 minute walk distance at 6 months. (NCT01406873)
Timeframe: Baseline to 6 months

Mean Change From Baseline in Manual Muscle Testing (MMT) Score

Manual muscle testing was performed on 26 muscle groups (shoulder abductors, elbow flexors, wrist flexors, wrist extensors, hip flexors, knee extensors, hip extensors, knee flexors, hip abductors, elbow extensors, ankle dorsiflexors, and plantar flexors on the right and left plus neck extensor and neck flexors). The muscles were tested in various positions including sitting, supine, prone, and side lying and each graded on a modification of the Medical Research Council (MRC) scale of 0 to 5 (5 representing normal strength). Average MMT score is derived by averaging the individual MMT scores across the 26 individual muscles. (NCT01406873)
Timeframe: Baseline to 6 months

Mean Change From Baseline in Quantitative Measure of Hand Grip Myotonia

Relaxation time of the long finger flexor muscles of the right hand after a maximum voluntary isometric contraction performed in a standardized fixed position of the right arm elbow/wrist/hand. Relaxation time for this measurement is defined as the time to relax from 90% to 5% of the maximum isometric force of contraction of the hand (the first of 6 serial contractions averaged over two consecutive trials performed 10 minutes apart). (NCT01406873)
Timeframe: Baseline to 6 months

Mean Change From Baseline in Patient-Reported Disease Burden and Quality of Life

"The Myotonic Dystrophy Health Index (MDHI) is a validated disease-specific measure of patient-reported disease burden. The MDHI total score is a weighted average derived from 17 subscales. MDHI total scores range form 0-100 with 0 representing no patient-reported disease burden and 100 representing the most severe patient-reported disease burden.~The Individualized Neuromuscular Quality of Life Questionnaire (INQoL) is a measure of quality of life in neuromuscular disease. The INQoL summary score is a weighted average made up of 5 sub-domains. Scores range from 0-100, and can be interpreted as the percent of maximal detrimental impact on quality of life with higher scores indicating more detrimental impact.~The 36-Item Short Form Survey (SF-36) is a generic measure of quality of life across 8 domains. Two summary metrics are produced from the 8 domains, ranging from 0-100% with lower scores representing worse levels of functioning." (NCT01406873)
Timeframe: Baseline to 6 months

Mean Change From Baseline in PR, QRS, and QTc Intervals, and Average Minimum Heart Rate (HR) Via Electrocardiogram (ECG) Monitoring

PR, QRS, and QTc intervals as well as average minimum heart rate (HR) were obtained through standard 12 lead electrocardiograms (ECGs). Values were computer generated and verified by the study investigator and study cardiologist. (NCT01406873)
Timeframe: Baseline to 6 Months

Percentage of Participants That Had a Dose Reduction or a Study Drug Withdrawal or Suspension Over 6 Months

Adverse events were monitored at the three in-person evaluations (Months 0, 3, and 6), at telephone evaluations every 2 weeks, and via patient-completed side effect diaries. The study investigators and safety monitoring committee reviewed adverse events and made decisions regarding drug withdrawals, suspensions, and dose reductions as needed. (NCT01406873)
Timeframe: 6 months

Clinical Eye Closure Myotonia Evaluation (Seconds)

Time to open the eyes after forced eye closure as measured on a stopwatch. (NCT00832000)
Timeframe: The end of period 1 (week 4) and the end of period 2 (week 9)

Clinical Hand Grip Myotonia Evaluation (Seconds)

The time to open the fist after a forced handgrip as measured on a stopwatch. (NCT00832000)
Timeframe: The end of period 1 (week 4) and the end of period 2 (week 9)

Compound Motor Action Potentials After Long Exercise Test

Compound muscle action potential (CMAP) after long periods of exercise as a percentage of baseline. (NCT00832000)
Timeframe: The end of period 1 (week 4) and period 2 (week 9)

Compound Motor Action Potentials After Short Exercise Test

The maximal post-exercise compound muscle action potential (CMAP) after short periods of exercise as a percent of the baseline measurement. (NCT00832000)
Timeframe: The end of period 1 (week 4) and period 2 (week 9)

Graded Myotonia by Needle Electromyography - Right Abductor Digiti Minimi

Measured the amount of myotonia present on needle exam by assigning a number 1-3, with 1 being minimal amount of myotonia on needle stick and 3 being maximal amount of myotonia present on needle stick. (NCT00832000)
Timeframe: The end of period 1 (week 4) and period 2 (week 9)

Graded Myotonia by Needle Electromyography - Right Tibialis Anterior

Measured the amount of myotonia present on needle exam by assigning a number 1-3, with 1 being minimal amount of myotonia on needle stick and 3 being maximal amount of myotonia present on needle stick. (NCT00832000)
Timeframe: The end of period 1 (week 4) and period 2 (week 9)

Individualized Neuromuscular Quality of Life Scale - Summary Score

Quality of life scale for patinets with neuromuscular disorders. The INQoL summary score is a weighted average made up of 5 subdomains (activities, social relationships, independence, emotions, and body image) which document the impact of a disease on a patients' quality of life. Scores range from 0-100, and can be interpreted as the percent of maximal detrimental impact on quality of life. A higher score indicates more detrimental impact. (NCT00832000)
Timeframe: The end of period 1 (week 4) and period 2 (week 9)

Patient Reported Pain on the IVR

Pain measured on a 1-9 scale, 1 being minimal, 9 the worst ever experienced. 0=no symptom reported. For analysis the average severity of pain for each participant was calculated from daily calls made in weeks 3-4 of each period. (NCT00832000)
Timeframe: Weeeks 3-4 of each period

Patient Reported Tiredness on the IVR

Tiredness measured on a 1-9 scale, 1 being minimal, 9 the worst ever experienced. 0=no symptom reported. For analysis the average severity of tiredness for each participant was calculated from daily calls made in weeks 3-4 of each period. (NCT00832000)
Timeframe: Weeks 3-4 of each period

Patient Reported Weakness on the IVR

Weakness measured on a 1-9 scale, 1 being minimal, 9 the worst ever experienced. 0=no symptom reported. For analysis the average severity of weakness for each participant was calculated from daily calls made in weeks 3-4 of each period. (NCT00832000)
Timeframe: Weeks 3-4 of each period

Patient-reported Stiffness on the IVR

Stiffness measured on a 1-9 scale, 1 being minimal, 9 the worst ever experienced. 0=no symptom reported. For analysis the average severity of stiffness for each participant was calculated from daily calls made in weeks 3-4 of each period. (NCT00832000)
Timeframe: Weeks 3-4 of each period

Quantitative Measure of Hand Grip Myotonia (Seconds)

Maximum voluntary contractions following forced right hand grip were recorded and the time to relax from 90% to 5% of average maximal force was determined using automated analysis software. (NCT00832000)
Timeframe: The end of period 1 (week 4) and period 2 (week 9)

Short Form 36 - Mental Composite Score

The SF-36 is a standard quality of life instrument. The mental composite score represents the the mental burden on quality of life and is a summary of questions related to mental impact of a disease or condition (mental function, role emotional, vitality, and mental health). The score is nomralized to the population and ranges from 0-100, with the US normal value of 50. A lower score represents a greater impact of quality of life. (NCT00832000)
Timeframe: The end of period 1 (week 4) and period 2 (week 9)

Short Form 36 - Physical Composite Score

The SF-36 is a standard quality of life instrument. The physical composite score represents the the physical burden on quality of life and is a summary of questions related to physical impact of a disease or condition (physical function, role physical, bodily pain, and general health). The score is nomralized to the population and ranges from 0-100, with the US normal value of 50. A lower score represents a greater impact of quality of life. (NCT00832000)
Timeframe: Particiapnts who experienced weakness on mexiletine in either period 1 or period 2.

Reviews

3 reviews available for mexiletine and Myotonia

Trials

5 trials available for mexiletine and Myotonia

Other Studies

20 other studies available for mexiletine and Myotonia